

Author: Elter Thomas Hallek Michael Engert Andreas
Publisher: Informa Healthcare
ISSN: 1465-6566
Source: Expert Opinion on Pharmacotherapy, Vol.7, Iss.12, 2006-08, pp. : 1641-1651
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


Management of Chronic Lymphocytic Leukaemia
Drugs & Aging, Vol. 16, Iss. 1, 2000-01 ,pp. :


By Singer Charles Goldstone Tony
Clinical Medicine, Vol. 1, Iss. 5, 2001-09 ,pp. :




Emerging drugs for chronic lymphocytic leukaemia
By Yee Karen WL O’Brien Susan M
Expert Opinion on Emerging Drugs, Vol. 11, Iss. 1, 2006-03 ,pp. :


Achieving Optimal Outcomes in Chronic Lymphocytic Leukaemia
By Hamblin T.J.
Drugs, Vol. 61, Iss. 5, 2001-01 ,pp. :